Cognition Therapeutics Receives U.S. Patent Covering A Polymorph Version Of Its Lead Drug Candidate Zervimesine

Cognition Therapeutics has been granted U.S. Patent No. 12,759,979 for a polymorph version of its lead drug candidate, zervimesine, which is set to expire in 2045, with potential for a five-year extension upon FDA approval. The patent covers the composition of matter, production process, and therapeutic methods for treating age-related degenerative disorders, including Alzheimer's disease and dry age-related macular degeneration.